Published in Medical Letter on the CDC and FDA, June 22nd, 2008
UCB also announced that the US FDA has accepted for filing and six-month priority review the supplementary New Drug Application (sNDA) for Keppra(R) as adjunctive treatment of partial onset seizures in infants and children with epilepsy, aged from one month to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.